Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13959674 | 0.96 | PDPK1 (0.44) | PDPK1 | |
| SCHEMBL13295766 | 0.87 | — | — | |
| SCHEMBL13937971 | 0.71 | PDPK1 (0.40) | PDPK1ALDH1A1 | |
| SCHEMBL30926135 | 0.67 | SMN1; SMN2 (0.39) | PDPK1ALDH1A1MAPK1 | |
| SCHEMBL6850314 | 0.65 | — | — | |
| SCHEMBL3311484 | 0.64 | PDPK1 (0.96) | PDPK1ALDH1A1 | |
| SCHEMBL2393815 | 0.64 | PDPK1 (0.96) | PDPK1ALDH1A1 | |
| SCHEMBL12256560 | 0.63 | PDPK1 (0.44) | PDPK1 | |
| SCHEMBL13959675 | 0.62 | LPO (0.31) | — | |
| SCHEMBL348289 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576077-B2 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-7576077-B2 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185095-A1 | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM5 | PDPK1 2854/4885ALDH1A1 2732/4885MAPK1 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.